US2016052912A1PendingUtilityA1
Diaminoheteroaryl substituted indazoles
Assignee: BAYER PHARMA AKITIENGESELLSCHAFTPriority: Mar 21, 2013Filed: Mar 19, 2014Published: Feb 25, 2016
Est. expiryMar 21, 2033(~6.6 yrs left)· nominal 20-yr term from priority
Inventors:Christoph-Stephan HilgerMarion HitchcockHans BriemGerhard SiemeisterAmaury Ernesto Fernandez-MontalvanJens SchröderSimon HoltonCornelia PreußeKarsten Denner
A61K 31/5377A61K 31/53A61K 31/506A61P 35/00A61K 45/06C07D 403/14A61K 31/695C07F 7/1804A61K 31/5383C07D 401/14C07D 403/04C07D 401/04C07D 498/04A61P 35/02
59
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Compounds of formula (I) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.
Claims
exact text as granted — not AI-modified1 . A compound of formula (I)
in which
X is CR 6 , N,
Y is CH, N,
R 1 is hydrogen, halogen, 1-3C-alkyl,
R 2 /R 3 are independently from each other hydrogen, halogen, cyano, hydroxy, 1-6C-haloalkyl, 1-6C-haloalkoxy, 1-6C-alkoxy,
R 4 is independently hydrogen, hydroxy, halogen, cyano, 1-6C-alkyl, 2-6C-alkenyl, 2-6C-alkynyl, 1-6C-haloalkyl, 1-6C-hydroxyalkyl, 1-6C-alkoxy, —O-(2-4C-alkylen)-O—C(O)-(1-4C-alkyl), 1-6C-haloalkoxy, —C(O)OR 9 , —C(O)-(1-6C-alkyl), —C(O)NR 10 R 11 , 3-7C-cycloalkyl, —S(O) 2 NH-(3-6C-cycloalkyl), —S(O) 2 NR 10 R 11 ,
heteroaryl which optionally is substituted independently one or more times with cyano, 1-4C-alkyl, 1-4C-haloalkyl, 1-4C-haloalkoxy,
whereby two of R 2 , R 3 (R 4 ) n , when positioned ortho to each other, may form together with the two carbon atoms to which they are attached, a heterocyclic 5-, 6- or 7-membered ring containing 1 or 2 heteroatoms selected from O or N, and optionally containing an additional double bond and/or optionally substituted by an oxo (═O) group and/or an 1-4C-alkyl group,
n 0, 1, 2 or 3
R 5 is (a) hydrogen;
(b) —C(O)-(1-6C-alkyl);
(c) —C(O)-(1-6C-alkylen)-O-(1-6C-alkyl);
(d) —C(O)NH-(1-6C-alkyl);
(e)
whereby
the * is the point of attachment;
R 6 is (a) hydrogen;
(b) hydroxy;
(c) cyano;
(d) 1-6C-alkoxy optionally substituted independently one or more times with
(d1) OH,
(d2) —O-(1-6C-alkyl),
(d3) —C(O)NR 10 R 11 ,
(d4) —NR 12 R 13 ,
(d5) —S-(1-6C-alkyl),
(d6) —S(O)-(1-6C-alkyl),
(d7) —S(O) 2 -(1-6C-alkyl),
(d8) —S(O) 2 NR 10 R 11 ,
(d9) heterocyclyl, which is optionally substituted with oxo (═O),
(d10) heteroaryl, which is optionally substituted independently one or more times with cyano, 1-4C-alkyl, 1-4C-haloalkyl, 1-4C-haloalkoxy, C(O)NR 10 R 11 , (1-4C-alkylen)-O-(1-4C-alkyl),
(e) —O-heteroaryl opt. subst. with CN,
(f)
whereby the * is the point of attachment,
(g) —O-(2-6C-alkylen)-O-(1-6C-alkyl) which is optionally substituted with hydroxy,
(h) —NR 12 R 13 ,
(i) —NHS(O) 2 -(1-6C-alkyl),
(j) —NHS(O) 2 -(1-6C-haloalkyl),
or
optionally, R 5 and R 6 form a 6-membered ring together with the nitrogen atom to which R 5 is attached and together with the pyrimidine ring carbon atoms to which R 5 —NH and R 6 are attached which may contain one further heteroatom selected from the group consisting of O, S, N,
and which is optionally substituted by an oxo (═O) group,
R 7 is
(a) hydrogen,
(b) 1-4C-alkyl, which is optionally substituted with heteroaryl
(c) 1-4C-haloalkyl,
(d) 2-4C-hydroxyalkyl,
(e)
whereby
the * is the point of attachment;
R 8 is independently hydrogen, halogen, hydroxy, 1-4C-alkyl, 1-4C-hydroxyalkyl, 1-4C-haloalkyl, 1-4C-haloalkoxy, C(O)OR 9 , C(O)NR 10 R 11 ,
m is 0, 1, 2, 3 or 4,
R 9 is
(a) hydrogen,
(b) 1-4C-alkyl which optionally is substituted with hydroxy,
R 10 , R 11 are independently from each other hydrogen, 1-4C-alkyl, 2-4C-hydroxyalkyl,
or
together with the nitrogen atom to which they are attached form a 4-6-membered heterocyclic ring optionally containing one further heteroatom selected from the group consisting of O, S or N, and which is optionally substituted with 1-2 fluorine atoms or C(O)OR 9 ,
R 12 , R 13 are independently from each other hydrogen, 1-4C-alkyl, 2-4C-hydroxyalkyl, —C(O)-(1-6C-alkyl), —C(O)-(1-6C-alkylen)-O-(1-6C-alkyl), —C(O)H, C(O)OR 9 ,
or
together with the nitrogen atom to which they are attached form a 4-6-membered heterocyclic ring optionally containing one further heteroatom selected from the group consisting of O, S or N, and which is optionally substituted by an oxo (═O) group,
or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.
2 . The compound of formula (I) according to claim 1 ,
wherein X is CR 6 , N, Y is CH, N, R 1 is hydrogen, halogen, 1-3C-alkyl, R 2 /R 3 are independently from each other hydrogen, halogen, cyano, hydroxy, 1-3C-haloalkyl, 1-3C-haloalkoxy, 1-3C-alkoxy, R 4 is independently hydrogen, hydroxy, halogen, cyano, 1-3C-alkyl, 2-3C-alkenyl, 2-3C-alkynyl, 1-3C-haloalkyl, 1-3C-hydroxyalkyl, 1-3C-alkoxy, —O-(2-4C-alkylen)-O—C(O)-(1-4C-alkyl), 1-3C-haloalkoxy, —C(O)OR 9 , —C(O)-(1-3C-alkyl), —C(O)NR 10 R 11 , 3-7C-cycloalkyl, —S(O) 2 NH-(3-6C-cycloalkyl), —S(O) 2 NR 10 R 11 , n 0, 1, R 5 is (a) hydrogen;
(b) —C(O)-(1-3C-alkyl);
(c) —C(O)-(1-3C-alkylen)-O-(1-3C-alkyl);
(d) —C(O)NH-(1-3C-alkyl);
(e)
whereby
the * is the point of attachment;
R 6 is (a) hydrogen;
(b) hydroxy;
(c) cyano;
(d) 1-3C-alkoxy optionally substituted independently one or more times with
(d1) OH,
(d2) —O-(1-3C-alkyl),
(d3) —C(O)NR 10 R 11 ,
(d4) —NR 12 R 13 ,
(d5) —S-(1-3C-alkyl),
(d6) —S(O)-(1-3C-alkyl),
(d7) —S(O) 2 -(1-3C-alkyl)
(d8) —S(O) 2 NR 10 R 11 ,
(d9) heterocyclyl, which is optionally substituted with oxo (═O),
(d10) heteroaryl, which is optionally substituted independently one or more times with cyano, 1-4C-alkyl, 1-4C-haloalkyl, 1-4C-haloalkoxy, C(O)NR 10 R 11 , (1-4C-alkylen)-O-(1-4C-alkyl),
(e) —O-heteroaryl opt. subst. with CN,
(f)
whereby the * is the point of attachment,
(g) —O-(2-3C-alkylen)-O-(1-3C-alkyl) which is optionally substituted with hydroxy,
(h) —NR 12 R 13 ,
(i) —NHS(O) 2 -(1-3C-alkyl),
(j) —NHS(O) 2 -(1-3C-haloalkyl),
or
optionally, R 5 and R 6 form a 6-membered ring together with the nitrogen atom to which R 5 is attached and together with the pyrimidine ring carbon atoms to which R 5 —NH and R 6 are attached which may contain one further heteroatom selected from the group consisting of O, S, N,
and which is optionally substituted by an oxo (═O) group,
R 7 is
(a) hydrogen,
(b) 1-4C-alkyl, which is optionally substituted with heteroaryl
(c) 1-4C-haloalkyl,
(d) 2-4C-hydroxyalkyl,
(e)
whereby
the * is the point of attachment;
R 8 is hydrogen, halogen, hydroxy, 1-4C-alkyl, 1-4C-hydroxyalkyl, 1-4C-haloalkyl, 1-4C-haloalkoxy, C(O)OR 9 , C(O)NR 10 R 11 ,
m is 0, 1
R 9 is (a) hydrogen,
(b) 1-4C-alkyl which optionally is substituted with hydroxy,
R 10 , R 11 are independently from each other hydrogen, 1-4C-alkyl, 2-4C-hydroxyalkyl,
or
together with the nitrogen atom to which they are attached form a 4-6-membered heterocyclic ring optionally containing one further heteroatom selected from the group consisting of O, S or N, and which is optionally substituted with 1-2 fluorine atoms or C(O)OR 9 ,
R 12 , R 13 are independently from each other hydrogen, 1-4C-alkyl, 2-4C-hydroxyalkyl, —C(O)-(1-3C-alkyl), —C(O)-(1-3C-alkylen)-O-(1-3C-alkyl), —C(O)H, C(O)OR 9 ,
or
together with the nitrogen atom to which they are attached form a 4-6-membered heterocyclic ring optionally containing one further heteroatom selected from the group consisting of O, S or N, and which is optionally substituted by an oxo (═O) group,
or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.
3 . The compound of formula (I) according to claim 1 ,
wherein X is CR 6 , N, Y is CH, N, R 1 is hydrogen, halogen, 1-3C-alkyl, R 2 /R 3 are independently from each other hydrogen, halogen, cyano, hydroxy, 1-3C-haloalkyl, 1-3C-haloalkoxy, 1-3C-alkoxy, R 4 is independently hydrogen, hydroxy, halogen, cyano, 1-3C-alkyl, 2-3C-alkenyl, 2-3C-alkynyl, 1-3C-haloalkyl, 1-3C-hydroxyalkyl, 1-3C-alkoxy, 1-3C-haloalkoxy, —C(O)OR 9 , —C(O)-(1-3C-alkyl), —C(O)NR 10 R 11 , —S(O) 2 NR 10 R 11 , n 0, 1, R 5 is (a) hydrogen;
(b) —C(O)-(1-3C-alkyl);
(c) —C(O)-(1-3C-alkylen)-O-(1-3C-alkyl);
(d) —C(O)NH-(1-3C-alkyl);
(e)
whereby
the * is the point of attachment;
R 6 is (a) hydrogen;
(b) hydroxy;
(c) cyano;
(d) 1-3C-alkoxy optionally substituted independently one or more times with
(d1) OH,
(d2) —O-(1-3C-alkyl),
(d3) —C(O)NR 10 R 11 ,
(d4) —NR 12 R 13 ,
(d5) —S-(1-3C-alkyl),
(d6) —S(O)-(1-3C-alkyl),
(d7) —S(O) 2 -(1-3C-alkyl)
(d8) —S(O) 2 NR 10 R 11 ,
(d9) heterocyclyl, which is optionally substituted with oxo (═O),
(d10) heteroaryl, which is optionally substituted independently one or more times with cyano, 1-4C-alkyl, 1-4C-haloalkyl, 1-4C-haloalkoxy, C(O)NR 10 R 11 , (1-4C-alkylen)-O-(1-4C-alkyl),
(e) —O-heteroaryl opt. subst. with CN,
(f)
whereby the * is the point of attachment,
(g) —O-(2-3C-alkylen)-O-(1-3C-alkyl) which is optionally substituted with hydroxy,
(h) —NR 12 R 13 ,
(i) —NHS(O) 2 -(1-3C-alkyl),
(j) —NHS(O) 2 -(1-3C-haloalkyl),
or
optionally, R 5 and R 6 form a 6-membered ring together with the nitrogen atom to which R 5 is attached and together with the pyrimidine ring carbon atoms to which R 5 —NH and R 6 are attached which may contain one further heteroatom selected from the group consisting of O,
and which is optionally substituted by an oxo (═O) group,
R 7 is
(a) hydrogen,
(b) 1-4C-alkyl, which is optionally substituted with heteroaryl
(c) 1-4C-haloalkyl,
(d) 2-4C-hydroxyalkyl,
(e)
whereby
the * is the point of attachment;
R 8 is hydrogen, halogen, hydroxy, 1-4C-alkyl, 1-4C-hydroxyalkyl, 1-4C-haloalkyl, 1-4C-haloalkoxy, C(O)OR 9 , C(O)NR 10 R 11 ,
m is 0,
R 9 is (a) hydrogen,
(b) 1-4C-alkyl which optionally is substituted with hydroxy,
R 10 , R 11 are independently from each other hydrogen, 1-4C-alkyl, 2-4C-hydroxyalkyl,
or
together with the nitrogen atom to which they are attached form a 4-6-membered heterocyclic ring optionally containing one further heteroatom selected from the group consisting of O, S or N, and which is optionally substituted with 1-2 fluorine atoms or C(O)OR 9 ,
R 12 , R 13 are independently from each other hydrogen, 1-4C-alkyl, 2-4C-hydroxyalkyl, —C(O)-(1-3C-alkyl), —C(O)-(1-3C-alkylen)-O-(1-3C-alkyl), —C(O)H, C(O)OR 9 ,
or
together with the nitrogen atom to which they are attached form a 4-6-membered heterocyclic ring optionally containing one further heteroatom selected from the group consisting of O
or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.
4 . The compound of formula (I) according to claim 1 ,
wherein X is CR 6 , N, Y is CH, N, R 1 is hydrogen, R 2 /R 3 are independently from each other hydrogen, halogen, R 4 is independently hydrogen, 1-3C-alkoxy, n 0, 1, R 5 is (a) hydrogen;
(b) —C(O)-(1-3C-alkyl);
(c) —C(O)-(1-3C-alkylen)-O-(1-3C-alkyl);
(d) —C(O)NH-(1-3C-alkyl);
(e)
whereby
the * is the point of attachment;
R 6 is (a) hydrogen;
(d) 1-3C-alkoxy optionally substituted independently one or more times with
(d1) OH,
(d2) —O-(1-3C-alkyl),
(h) NR 12 R 13 ,
(i) —NHS(O) 2 -(1-3C-alkyl),
(j) —NHS(O) 2 -(1-3C-haloalkyl),
or
optionally, R 5 and R 6 form a 6-membered ring together with the nitrogen atom to which R 5 is attached and together with the pyrimidine ring carbon atoms to which R 5 —NH and R 6 are attached which may contain one further heteroatom selected from the group consisting of O,
and which is optionally substituted by an oxo (═O) group,
R 7 is
(a) hydrogen,
((e)
whereby
the * is the point of attachment;
R 8 is hydrogen,
m is 0,
R 12 , R 13 are independently from each other hydrogen, —C(O)-(1-3C-alkylen)-O-(1-3C-alkyl),
or
together with the nitrogen atom to which they are attached form a 4-6-membered heterocyclic ring optionally containing one further heteroatom selected from the group consisting of O
or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.
5 . The compound of formula (I) according to claim 1 ,
wherein X is CR 8 , N, Y is CH, N, R 1 is hydrogen, R 2 /R 3 are independently from each other hydrogen, fluorine, R 4 is independently hydrogen, 1-3C-alkoxy, n 0, 1, R 5 is (a) hydrogen;
(b) —C(O)—CH 3 ,
(c) —C(O)-(methylen)-O-(methyl);
(d) —C(O)NH-(1-3C-alkyl);
(e)
whereby
the * is the point of attachment;
R 6 is (a) hydrogen;
(d) 1-3C-alkoxy optionally substituted independently one or more times with
(d1) OH,
(d2) —O-(methyl),
(h) —NR 12 R 13 ,
(i) —NHS(O) 2 -(1-3C-alkyl),
(j) —NHS(O) 2 —(CF 3 ),
or
optionally, R 5 and R 6 form a 6-membered ring together with the nitrogen atom to which R 5 is attached and together with the pyrimidine ring carbon atoms to which R 5 —NH and R 6 are attached which may contain one further oxygen atom,
and which is optionally substituted by an oxo (═O) group,
R 7 is
(a) hydrogen,
(e)
whereby
the * is the point of attachment;
R 8 is hydrogen,
m is 0,
R 12 , R 13 are independently from each other hydrogen, —C(O)-(1-3C-alkylen)-O-(1-3C-alkyl),
or
together with the nitrogen atom to which they are attached form a 6-membered heterocyclic ring containing one further oxygen atom
or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.
6 . A compound of formula (I) according to claim 1 , which is selected from the group consisting of:
2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-N-(pyridin-4-yl)pyrimidine-4,6-diamine, 2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-N,N′-di(pyridin-4-yl)pyrimidine-4,6-diamine, N-{2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-6-(pyridin-4-ylamino)-pyrimidin-4-yl}acetamide, N-{2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-6-(pyridin-4-ylamino)pyrimidin-4-yl}-2-methoxyacetamide, N-{6-(dipyridin-4-ylamino)-2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-pyrimidin-4-yl}acetamide, N-{6-(dipyridin-4-ylamino)-2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]pyrimidin-4-yl}-2-methoxyacetamide, 2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-N-(pyridin-4-yl)-pyrimidine-4,6-diamine, 2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidine-4,6-diamine, 2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-(morpholin-4-yl)-N-(pyridin-4-yl)pyrimidine-4,6-diamine, 1-{2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-(morpholin-4-yl)-6-(pyridin-4-ylamino)pyrimidin-4-yl}-3-ethylurea, 2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-N-(pyrimidin-4-yl)pyrimidine-4,6-diamine, 2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyrimidin-4-yl)pyrimidine-4,6-diamine, 2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-(morpholin-4-yl)-N-(pyrimidin-4-yl)pyrimidine-4,6-diamine, 1-{2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-(morpholin-4-yl)-6-(pyrimidin-4-ylamino)pyrimidin-4-yl}-3-ethylurea, 6-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-N-(pyridin-4-yl)-1,3,5-triazine-2,4-diamine, 2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-(2-methoxyethoxy)-N-(pyridin-4-yl)pyrimidine-4,6-diamine, 2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-(2-methoxyethoxy)-N-(pyrimidin-4-yl)pyrimidine-4,6-diamine, N-{4-amino-2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-6-(pyridin-4-ylamino)pyrimidin-5-yl}-2-methoxyacetamide, N-{4-amino-2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-6-(pyrimidin-4-ylamino)pyrimidin-5-yl}-2-methoxyacetamide, N-{4-amino-2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-6-(pyridin-4-ylamino)pyrimidin-5-yl}ethanesulfonamide, N-{4-amino-2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-6-(pyridin-4-ylamino)pyrimidin-5-yl}-1,1,1-trifluoromethanesulfonamide 2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)-6H-pyrimido[5,4-b][1,4]oxazin-7(8H)-one, 2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-4-(pyrimidin-4-ylamino)-6H-pyrimido[5,4-b][1,4]oxazin-7(8H)-one, 2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-N,N′-di(pyridine-4-yl)pyrimidine-4,6-diamine, 2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-methoxy-N,N′-di(pyridin-4-yl)pyrimidine-4,6-diamine, 2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-(morpholin-4-yl)-N,N′-di(pyridin-4-yl)pyrimidine-4,6-diamine, 2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-(morpholin-4-yl)-N,N′-di(pyrimidin-4-yl)pyrimidine-4,6-diamine, 6-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-N,N′-di(pyridin-4-yl)-1,3,5-triazine-2,4-diamine, 2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-(2-methoxyethoxy)-N,N′-di(pyridin-4-yl)pyrimidine-4,6-diamine, 2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-(2-methoxyethoxy)-N,N′-di(pyrimidin-4-yl)pyrimidine-4,6-diamine, N-{2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-4,6-bis(pyridin-4-ylamino)pyrimidin-5-yl}-2-methoxyacetamide, N-{2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-4,6-bis(pyrimidin-4-ylamino)pyrimidin-5-yl}-2-methoxyacetamide, N-{2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-4,6-bis(pyridin-4-ylamino)pyrimidin-5-yl}ethanesulfonamide, N-{2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-4,6-bis(pyridin-4-ylamino)pyrimidin-5-yl}-1,1,1-trifluoromethanesulfonamide, 2-({4-amino-2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-6-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)ethanol, and 2-({2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-4,6-bis-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)ethanol,
or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.
7 . (canceled)
8 . A method for the treatment of a hyperproliferative disease or disorder responsive to induction of cell death comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1 or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.
9 . The method according to claim 8 , wherein the hyperproliferative disease or disorder responsive to induction of cell death is selected from haemotological tumours, solid tumours and metastases thereof.
10 . The method according to claim 9 , wherein the tumor is selected from cervical tumors and metastases thereof.
11 . A pharmaceutical composition comprising a compound according to claim 1 or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer, together with at least one pharmaceutically acceptable auxiliary.
12 . (canceled)
13 . A combination comprising a compound according to claim 1 or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer, and an additional active ingredient selected from chemotherapeutic anti-cancer agents and target-specific anti-cancer agents.
14 . A compound selected from:
whereby R 1 , R 2 , R 3 R 4 R 6 and n have the meaning according to claim 1 ;
whereby R 1 , R 2 , R 3 R 4 and n have the meaning according to claim 1 ;
whereby R 1 , R 2 , R 3 , R 4 and n have the meaning according to claim 1 ;
whereby R 1 , R 2 , R 3 , R 4 and n have the meaning according to claim 1 .
15 . (canceled)Join the waitlist — get patent alerts
Track US2016052912A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.